**Claims**

1. A multi-specific antibody molecule comprising or consisting of:

   a) a polypeptide chain of formula (**I**):

   $$\mathbf{V_H\text{-}CH_1\text{-}X\text{-}V_1}; \text{ and}$$

   b) a polypeptide chain of formula (**II**):

   $$\mathbf{V_L\text{-}C_L\text{-}Y\text{-}V_2};$$

   wherein:

   $V_H$ represents a heavy chain variable domain;

   $CH_1$ represents a domain of a heavy chain constant region, for example domain 1 thereof;

   X represents a bond or linker;

   Y represents a bond or linker;

   $V_1$ represents a dsFv or a dsscFv;

   $V_L$ represents a light chain variable domain;

   $C_L$ represents a domain from a light chain constant region, such as Ckappa;

   $V_2$ represents a dsFv or a dsscFv.

2. A multi-specific antibody molecule according to claim 1, wherein X is a linker.
3. A multi-specific antibody molecule according to any one of claims 1 to 2, wherein Y is a linker.
4. A multi-specific antibody molecule according to any one of claims 1 to 3, wherein $V_1$ is a dsFv and $V_2$ is a dsFv.
5. A multi-specific antibody molecule according to any one of claims 1 to 3, wherein $V_1$ is a dsscFv and $V_2$ is a dsscFv.
6. A multi-specific antibody molecule according to any one of claims 1 to 3, wherein $V_1$ is a dsscFv and $V_2$ is a dsFv, or wherein $V_1$ is a dsFv and $V_2$ is a dsscFv.
7. A multi-specific antibody molecule according to any one of claims 1 to 6, wherein the light chain variable domain or the heavy chain variable domain of $V_1$ is attached to X, for example through a peptide bond.
8. A multi-specific antibody molecule according to any one of claims 1 to 7, wherein the light chain variable domain or the heavy chain variable domain of $V_2$ is attached to Y, for example through a peptide bond.
9. A multi-specific antibody molecule according to any one of claims 1 to 8, wherein the light chain and heavy chain variable domains of $V_1$ and/or the light chain and heavy chain variable domains of $V_2$ are linked by a disulfide bond between two engineered cysteine residues.

10. A multi-specific antibody molecule according to any one of claims 1-9, wherein the heavy chain and light chain variable domains of $V_1$ and/or $V_2$ are linked by a disulfide bond between two cysteine residues, wherein the position of the pair of cysteine residues is selected from the group comprising or consisting of: $V_H37$ and $V_L95$, $V_H44$ and $V_L100$, $V_H44$ and $V_L105$, $V_H45$ and $V_L87$, $V_H100$ and $V_L50$, $V_H100b$ and $V_L49$, $V_H98$ and $V_L46$, $V_H101$ and $V_L46$, $V_H105$ and $V_L43$ and $V_H106$ and $V_L57$ (numbering according to Kabat), wherein the $V_H$ and $V_L$ values are independently selected within a given $V_1$ or $V_2$.
11. A multi-specific antibody molecule according to claim 10, wherein the position of the pair of engineered cysteine residues is $V_H44$ and $V_L100$.
12. A multi-specific antibody molecule according to any one of claims 1 to 11, wherein X is a peptide linker.
13. A multi-specific antibody molecule according to claim 12 wherein X is a peptide linker selected from SEQ ID NO: 1, 2, 69 and 70.
14. A multi-specific antibody molecule according to any one of claims 1 to 13, wherein Y is a peptide linker.
15. A multi-specific antibody molecule according to claim 14, wherein Y is a peptide linker selected from SEQ ID NO: 1, 2, 69 and 70.
16. The multi-specific antibody molecule according to any one of claims 1 to 15 which is tri-specific.
17. The tri-specific antibody molecule according to claim 16 wherein each of the three binding domains bind different antigens.
18. A polynucleotide encoding a multi-specific antibody molecule according to any one of claims 1 to 17.
19. A vector comprising a polynucleotide defined in claim 18.
20. A host cell comprising the polynucleotide or vector of claim 18 or 19 respectively.
21. A host cell comprising two or three vectors each vector comprising a polynucleotide encoding a different polypeptide chain of a multi-specific antibody molecule according to any one of claims 1 to 17.
22. A process comprising expressing a multi-specific antibody molecule from a host cell defined in claim 20 or claim 21.
23. A pharmaceutical composition comprising a multi-specific antibody molecule according to any one of claims 1 to 17 and at least one excipient.
24. A multi-specific antibody molecule according to any one of claims 1 to 17 or a pharmaceutical composition according to claim 23 for use in treatment.